| Prev Close: | 28.90 |
|---|---|
| Open: | 29.03 |
| Bid: | 29.15 x 500 |
| Ask: | 29.25 x 5800 |
| 1y Target Est: | 31.16 |
| Beta: | 0.81 |
| Next Earnings Date: | 29-Jul-13 |
| Day's Range: | 28.99 - 29.33 |
|---|---|
| 52wk Range: | 21.40 - 31.15 |
| Volume: | 31,860,461 |
| Avg Vol (3m): | 31,537,500 |
| Market Cap: | 210.42B |
| P/E (ttm): | 15.08 |
| EPS (ttm): | 1.94 |
| Div & Yield: | 0.96 (3.20%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
- How Health Care Is Mining, Using Your DataBig Data Download
- What Stocks to Sell – and Buy – in MayMichael Santoli
Headlines
- Athersys Has Some Promise, But Controversy And Doubt Remainat Seeking Alpha(Thu 4:06PM EDT)
- Stagflationary, Muddling, Sideways Economy And Marketat Seeking Alpha(Thu 3:51PM EDT)
- China's Parents Crave Illegally Imported Baby Formulaat BusinessWeek(Thu 3:47PM EDT)
- Business events scheduled for the coming weekAP(Thu 2:13PM EDT)
- 3M Unitek Launches APC Appliance System and 2 Other Dow Movers To Watchat Wall St. Cheat Sheet(Thu 1:49PM EDT)
- Midday Glance: Pharmaceuticals companiesAP(Thu 1:26PM EDT)
- Aveo Fails to Win FDA Panel Backing for Kidney Cancer Drugat Bloomberg(Thu 1:05PM EDT)
- UPDATE 2-Shares of ING U.S. rise in NYSE debutat Reuters(Thu 11:34AM EDT)
- Key Earnings this Weekat Motley Fool(Thu 10:16AM EDT)
- ING U.S. Kicks Off 2nd Biggest IPO of '13 in the Redat Fox Business(Thu 9:53AM EDT)
- Pfizer's Efforts Boost Pain Therapeutics And Durect Corp.at Seeking Alpha(Thu 8:05AM EDT)
- Sanofi earnings slashed in first quarterAP(Thu 2:53AM EDT)
- Why Did Pain Therapeutics Increase Over 25%?at Seeking Alpha(Thu 1:15AM EDT)
- Oregon Health Experiment Shows That Having Health Insurance Is Different Than Being Healthyat Forbes(Thu 12:04AM EDT)
- Take 2 Dividend Stocks and Call Me in the Morningat Motley Fool(Wed, May 1)
Press Releases
- Pfizer Reports First-Quarter 2013 ResultsBusiness Wire(Tue, Apr 30)
- Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 DiabetesBusiness Wire(Mon, Apr 29)
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 YearsBusiness Wire(Sun, Apr 28)
Reports
- PFE: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- Thomson Reuters Stock Report - PFIZER INC. (PFE-N)Thomson Reuters Stock Report(May 2)
- Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive PotentialStreetwise Reports(May 2)